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ON BEHALF OF THE RISC INVESTIGATORS*
OBJECTIVEdWe evaluated whether the association of insulin sensitivity with HDL choles-
terol (HDL) and triglycerides is inﬂuenced by major plasma apolipoproteins, as suggested by
recent experimental evidence.
RESEARCH DESIGN ANDMETHODSdThis study included a cross-sectional analysis
of the RISC Study, a multicenter European clinical investigation in 1,017 healthy volunteers
balanced in sex (women 54%) and age strata (range 30–60 years). Insulin sensitivity (M/I inmmol
zmin21 z kgFFM
21 z nM21) wasmeasured by the clamp technique and apolipoproteins (ApoB, -C3,
-A1, and -E) by Multiplex Technology.
RESULTSdThe center-, sex-, and age-adjusted standardized regression coefﬁcients (STDb)
with M/I were similar for HDL and triglycerides (+19.9 6 1.9 vs. 220.0 6 2.0, P , 0.0001).
Further adjustment for triglycerides (or HDL), BMI, and adiponectin (or nonesteriﬁed fatty acid)
attenuated the strength of the association of M/I with bothHDL (STDb +6.46 2.3, P, 0.01) and
triglycerides (29.5 6 2.1, P , 0.001). Neither ApoA1 nor ApoE and ApoB showed any asso-
ciation with M/I independent from plasma HDL cholesterol and triglycerides. ApoC3, in con-
trast, in bothmen andwomen, was positively associatedwithM/I independently of plasma lipids.
A relative enrichment of plasma lipids with ApoC3 is associated with lower body fat percentage
and lower plasma alanine amino transferase.
CONCLUSIONSdOur results suggest that HDL cholesterol modulates insulin sensitivity
through a mechanism that is partially mediated by BMI and adiponectin but not by ApoA1.
Similarly, the inﬂuence of triglycerides on insulin sensitivity is in part mediated by BMI and is
unrelated to ApoE or ApoB, but it is signiﬁcantly modulated by ApoC3, which appears to protect
from the negative effect of plasma lipids.
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The dyslipidemia characterized byelevated plasma triglycerides andlow HDL cholesterol is one of the
key components of the metabolic syn-
drome, and there is evidence that it is
secondary to the presence of insulin re-
sistance and obesity (1). However, recent
data suggest that serum lipoproteins exert
an inﬂuence on tissue insulin sensitivity
both directly and through the activity of
their major lipoproteins. HDL particles
and apolipoprotein A-I (ApoA1) might
indirectly modulate insulin sensitivity
through their antioxidant and anti-
inﬂammatory action (2), their effect on
energy expenditure (3), and/or their close
relationships with adiponectin (4,5).
Apolipoproteins CIII (ApoC3) and E
(ApoE), which are present both in VLDL
and HDL particles, have the potential to
modulate whole-body insulin sensitivity
by regulating the transfer of plasma trigly-
cerides and nonesteriﬁed fatty acids (FFAs)
to tissues. ApoC3, the second most abun-
dant apolipoprotein circulating in human
plasma, is a natural lipoprotein lipase in-
hibitor (6–8). When exposed to a high-fat
diet, APOC3 gene knockout mice display
lower serum triglycerides but more severe
obesity and insulin resistance, which are
caused by excess FFA transfer from plasma
to tissues (9).
Data in humans are scarce and con-
ﬂicting. Higher ApoC3 levels have been
reported in subjects with increased trigly-
cerides, insulin resistance, cardiovascular
disease, and type 2 diabetes (10–12).
However, the contribution of ApoC3, in-
dependent of triglycerides, remains un-
clear. Although studies on the human
APOC3 gene have failed to show clear asso-
ciations between mutations and altered
lipid/lipoprotein metabolism (7), interest-
ingly, APOC3 polymorphisms rs2854116
and rs2854117 are associatedwith a relative
poverty of ApoC3 (with respect to serum
triglycerides), increased liver triglyceride
content, and insulin resistance (13). Simi-
larly, in middle-aged men with the meta-
bolic syndrome, lower ApoC3 levels were
associated with a higher visceral fat mass
and lower plasma triglycerides (14).
Data from experimental animals sug-
gest that ApoE is opposite to ApoC3, its
lack being associated with resistance to the
development of both diet-induced obesity
and insulin resistance (15). In humans, el-
evated levels of ApoE are consistently
found in obesity, insulin resistance, and
dyslipidemia (16), and all these factors, in
turn, have been shown to upregulate ApoE
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and VLDL production (17). Therefore, it is
particularly difﬁcult to evaluate whether
ApoE modulates insulin sensitivity inde-
pendently of serum triglycerides and obe-
sity. Also the studies on ApoE ´2/´3/´4
polymorphisms have not reached consis-
tent conclusions. The Framingham Off-
spring Study found that none of these
polymorphisms was associated with insu-
lin resistance (18), whereas other studies
(19–21) have observed that the polymor-
phisms modify the strength of the associa-
tions between insulin resistance and
dyslipidemia.
In conclusion, although experimental
data suggest a role for apolipoproteins in
modulating insulin sensitivity,whether this
holds true in humans remains unclear.
Possible reasons are that in most previous
studies, insulin sensitivity was not directly
measured but only estimated through
plasma insulin and glucose levels, and/or
that the strategies to dissect the effect of the
apolipoproteins from that of lipoprotein as
well as from their confounders were not
always appropriate.
To directly address the question of
whether ApoA1, ApoC3, and ApoE mod-
ulate the relationships of serum lipids
with insulin sensitivity, we exploited the
RISC (Relationship between Insulin Sen-
sitivity and Cardiovascular disease) Study
(22), one of the largest collections of sub-
jects in which insulin sensitivity was mea-






RISC is a prospective, observational co-
hort study; the rationale and methodol-
ogy have been described previously (22).
In brief, participants were recruited at 19
centers in 14 European countries, accord-
ing to the following inclusion criteria: ei-
ther sex, age 30–60 years, and clinically
healthy. Exclusion criteria were as fol-
lows: treatment for any chronic disease,
pregnancy, any cardiovascular event,
weight change of$5 kg in last 3 months,
cancer (in the last 5 years), and renal or
liver failure, arterial blood pressure
$140/90 mmHg, fasting plasma glucose
$7.0 mmol/L, 2-h plasma glucose (on a
standard 75-g oral glucose tolerance test)
$11.0 mmol/L, total serum cholesterol
$7.8 mmol/L, serum triglycerides $4.6
mmol/L, or electrocardiogram abnormal-
ities. The present analysis is based on the
baseline data of 1,017 subjects who satis-
ﬁed all criteria and in whom the apolipo-
proteins were measured. Local ethics
committee approval was obtained by
each recruiting center.
Lifestyle and medical history
Information on menopause, as well as on
smoking habits and alcohol consumption,
was collected by the MD responsible for
the study. Smoking status was categorized
as current, ex, or never and only referred
to cigarette smoking. Physical activity was
assessed by means of the International
Physical Activity Questionnaire (IPAQ)
(www.ipaq.ki.se), a validated estimate for
the number of metabolic equivalents per
week; these estimates were compacted
into a three-level score: 1, inactive; 2, min-
imally active; and 3, health-enhancing
physical activity.
Physical examinations
Height was measured on a clinic stadio-
meter, and body weight, percent body fat,
and fat-free mass (FFM) were evaluated by
bioimpedance (Tanita International Divi-
sion, Tokyo, Japan). Sitting blood pressure
and heart rate were measured (OMRON
705 cp; OMRON Healthcare Europe,
Hoofddorp, the Netherlands) three times
over 10 min, and the median value was
used in statistical analyses.
Insulin clamp
Euglycemic-hyperinsulinemic clamp was
performed in all subjects. Exogenous
insulin was administered as a primed-
continuous infusion at a rate of 240 pmol/
min/m2 simultaneously with a variable
20% dextrose infusion adjusted every
5–10 min to maintain plasma glucose level
within 15% of the target glucose level
(4.5–5.5 mmol/L). Additional blood sam-
ples were obtained at 20-min intervals for
insulin and FFA determination.
Analytical methods
Blood was separated into plasma and
serum, aliquoted, and stored at 2808C
for centralized analyte determination. Se-
rum total cholesterol, HDL cholesterol,
LDL cholesterol, and triglycerides were
measured by enzymatic colorimetric test
(Roche Modular Systems), FFA by an im-
munoenzymatic assay (Randox), and
plasma insulin and C-peptide by a two-
sited, time-resolved ﬂuoroimmunoassay
(AutoDELFIA Insulin Kit; Wallac Oy,
Turku, Finland). Serum ApoA1, -A2,
-B100, -C3, and -E were assayed with
Milliplex APO-62 K kits on a Bio-Plex
200 System instrument (Bio-Rad Laborato-
ries). Serum adiponectin was measured by
an in-house time-resolved immunoﬂuoro-
metric assay based on two antibodies and
recombinant human adiponectin (R&D
Systems, Abingdon, U.K.), as previously
described (23).
Calculations
Insulin sensitivity (M/I, in units of mmol z
min21 z kgFFM
21 z nM21) was expressed as
the ratio of the M value, averaged over the
ﬁnal 40 min of the 2-h clamp and normal-
ized by the FFM, to the mean plasma in-
sulin concentration measured during the
same interval (24).
Statistical analysis
Data are reported as mean 6 SD. Differ-
ences between means and prevalence
rates have been evaluated with Student
t test and x2, respectively. General linear
models (standard least square) were used
to test the simultaneous dependence of
continuous variables on single ormultiple
parameters. Since none of the lipid vari-
ables displayed a normal distribution, we
preliminarily veriﬁed the consistency of
the correlations by comparing Pearson r
and Spearman r of the nontransformed
variable with the Pearson r of the log
transformed (Supplementary Table 1).
Since all the correlation coefﬁcients were
similar, we used the standardized (values/
sex-speciﬁc SD) plasma lipids and apoli-
poproteins to allow a direct comparison
between variables that is independent of
their units and their biological range. The
estimated regression coefﬁcients were
therefore called standardized regression
coefﬁcients (STDb) and expressed
as value 6 SEM. Two-way ANOVA and
ANCOVA were used for group compari-
sons while controlling for covariates. A
two-tailed P value of #0.05 was consid-
ered statistically signiﬁcant. All analyses
were run on JMP 9.0.1.
RESULTSdMen and women differed
with respect to insulin sensitivity, anthro-
pometric and metabolic characteristics,
and lipid proﬁle (Table 1), with women
showing an overall healthier proﬁle
despite a higher fat mass and plasma
FFA concentrations. ApoC3 and ApoB
were lower in women than men, whereas
ApoA1 was higher; ApoE did not show a
sex difference. Menopause was associated
with a diffuse (10–15%) increment in all
apolipoproteins and lipoproteins, with
the exception of HDL cholesterol, which
remained stable, whereas in men older
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than 50 years, a smaller (5%) increment in
total and LDL cholesterol was observed.
In univariate analysis (Supplemen-
tary Table 1), insulin sensitivity was pos-
itively associated with HDL cholesterol
and negatively with triglycerides. The
strength of the association was higher
for HDL cholesterol than triglycerides
and tended to be higher in men than
women (STDb = +23.3 6 3.0 vs. +19.0 6
2.7 and 221.6 6 3.0 vs. 214.5 6 2.9,
respectively, P , 0.0001 for all). LDL
cholesterol was inversely associated with
M/I in both men and women with lower
STDb values (28.3 6 3.1 and 26.9 6
2.7, respectively, P , 0.02 for both) that
became nonstatistically signiﬁcant when
adjusted for HDL cholesterol and trigly-
cerides. In both men and women,
ApoA1 (STDb = +8.6 6 3.0 and +7.0 6
2.8, respectively) showed a direct associa-
tion with insulin sensitivity that, however,
was not independent of HDL cholesterol
(adjusted STDb =22.46 3.3 and +0.46
2.9, P = NS for both). ApoB and ApoE
were strongly correlated with insulin sen-
sitivity only in men (STDb =231.96 7.3
and212.86 2.9, P, 0.0001); however,
neither resulted independently of plasma
triglycerides and HDL cholesterol.
ApoC3, interestingly, that was negatively
associated with M/I only in men (STDb =
28.66 3.1), when adjusted for triglycer-
ides became positively correlated with in-
sulin sensitivity both in men and women
(STDb = +6.96 3.4 and +10.96 3.1, P,
0.05 for both). ApoA2 was not correlated
to M/I in either sex. Pre- and postmeno-
pausal women had a superimposable pat-
tern of associations.
The strength of the associations be-
tween insulin sensitivity and HDL choles-
terol and triglycerides in multivariate
analysis after progressive adjusting for po-
tential confounders is shown in Fig. 1,
where the predicted changes in M/I
(6SEM) for one SD change of either
plasma lipid are illustrated. After adjusting
for age, center, and sex (model a), the pre-
dicted impact of HDL cholesterol and tri-
glycerides was similar (STDb = +19.9 6
1.9 and220.46 2.0, respectively); further
adjustment for the cognate lipid (model b)
and BMI (model c) approximately halved
the estimate, and adjustment for physical
activity and smoking had no additional ef-
fect (model d).We then introduced into the
model variables that could be relevant as
mechanisms, i.e., adiponectin for HDL
and FFA for triglycerides. Whereas the
former caused a 35% decline in the esti-
mated effect of HDL on M/I, FFA entry
into the model was associated with only a
15% reduction in the estimated effect of
triglycerides (model e). We then evaluated
the impact of the major associated lipopro-
teins; whereas ApoA1 caused a further mi-
nor reduction of the estimated effect of
HDL, which became of borderline statisti-
cal signiﬁcance (P = 0.04), adjusting for
ApoC3 caused a 25% increase in the esti-
mated impact of a change in triglycerides
on M/I (model f).
In two stepwise multiple regression
models using as independent variables
the two sets (for HDL and triglycerides)
included in Fig. 1, HDL cholesterol
ranked after BMI, adiponectin, physical
activity, triglycerides, and sex and before
smoking, together explaining 35% of M/I
variability; ApoA1 did not enter into the
model; triglycerides ranked after BMI,
HDL, sex, FFA, and physical activity and
before smoking and ApoC3 (which had a
positive coefﬁcient), together explaining
35% of M/I variability.
The role of adiponectin in explaining
the relationship between HDL cholesterol
and insulin sensitivity also emerges from
the strong association between the two
Table 1dAnthropometric, lifestyle, and metabolic characteristics of study subjects
Women Men P
n 556 461
Age (years) 45 6 8 44 6 9 0.046
Waist (cm) 81 6 11 93 6 10 ,0.0001
BMI (kg/m2) 24.7 6 4.1 26.1 6 3.4 ,0.0001
Body fat mass (%) 22.7 6 9.3 19.3 6 7.9 ,0.0001
Systolic blood pressure (mmHg) 114 6 13 122 6 10 ,0.0001
Diastolic blood pressure (mmHg) 73 6 8 76 6 7 ,0.0001
IPAQ (% score 1/2/3) 19/44/37 20/42/38 NS
Alcohol intake (g/week) 54 6 65 104 6 97 ,0.0001
Smokers (never/current/ex, %) 46/24/30 46/26/28 NS
Menopause (%) 25.9 d d
Fasting plasma glucose (mmol/L) 4.96 6 0.51 5.20 6 0.49 ,0.0001
M/I (mmol z min21 z kgFFM
21 z nM21) 156 6 66 126 6 65 ,0.0001
Adiponectin (mg/L) 9.97 6 3.82 6.59 6 2.59 ,0.0001
Total cholesterol (mmol/L) 4.83 6 0.87 4.93 6 0.86 NS
LDL cholesterol (mmol/L) 2.83 6 0.81 3.10 6 0.77 ,0.0001
HDL cholesterol (mmol/L) 1.57 6 0.38 1.26 6 0.30 ,0.0001
Triglycerides (mmol/L) 0.94 6 0.44 1.25 6 0.70 ,0.0001
FFA (mmol/L) 0.59 6 0.21 0.47 6 0.19 ,0.0001
ApoA1 (mg/dL) 139 6 28 126 6 24 ,0.0001
ApoA2 (mg/dL) 33 6 11 34 6 10 NS
ApoB (mg/dL) 123 6 50 137 6 57 ,0.0001
ApoC3 (mg/dL) 17.4 6 6.8 18.8 6 8.9 ,0.007
ApoE (mg/dL) 5.14 6 1.90 5.30 6 2.04 NS
ALT (units/L) 20 6 14 21 6 13 NS
Data entries are means6 SD. P refers to the statistical signiﬁcance of Student t test or x2. IPAQ, International
Physical Activity Questionnaire.
Figure 1dEstimated effects (and SE) of +1 SD
of serum HDL cholesterol (top) and +1 SD of
serum triglycerides (bottom) on insulin sen-
sitivity (expressed as M/I). The lowercase let-
ters indicate the different set of variables that
were included in the different models: center,
age, and sex (a); a + serum triglycerides for
HDL or serum HDL cholesterol for trigly-
cerides (b); b + BMI (c); c + smoking and
physical activity (d); d + adiponectin for HDL
and FFA for triglycerides (e); e + ApoA1 for
HDL or ApoC3 for triglycerides (f).
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variables in both women and men (r =
0.36 and r = 0.40, respectively) (Fig. 2
and Supplementary Fig. 1). Of note, in a
stepwise model predicting plasma adipo-
nectin concentration in the entire cohort,
HDL cholesterol ranked ﬁrst (with r2 =
0.25) followed by sex (r2 = 0.32), waist
girth (r2 = 0.34), and age (r2 = 0.35).
In an attempt to better understand the
interaction of ApoC3 and triglyceride
levels onM/I, we compared the regression
slopes for the simple linear bivariate re-
gression with the regression slopes when
both variables were simultaneously in-
cluded in a multivariate analysis. As
shown in Fig. 2, after adjusting for trigly-
cerides, ApoC3 was positively associated
with M/I, whereas after adjusting for
ApoC3, the association between M/I
and serum triglycerides became steeper
(P, 0.001 for slope comparison). In ad-
dition to the isolated effects of triglycerides
(negative) and ApoC3 (positive), the inter-
action was also statistically signiﬁcant (P
, 0.02) and negative. The positive asso-
ciation between ApoC3 and M/I once ad-
justed for triglycerides was present in both
men and women (Fig. 2A, inset), whereas
the change of the slope of triglycerides ver-
sus M/I after adjusting for Apo3 (Fig. 2B,
inset) showed a trend similar to the whole
population but failed to reach statistical
signiﬁcance in either sex. Neither meno-
pause in women nor age.50 years inmen
(entered in the model as covariates) mod-
iﬁed by any extent the values of the slopes
or the errors of the estimate.
To test whether by chronically limit-
ing lipoprotein lipase activity ApoC3
might also reduce topic and/or ectopic
fat deposition, we grouped subjects into
tertiles of triglyceride with progressively
higher ApoC3 enrichment (ApoC3 to
triglycerides ratio) and then compared
body fat and serum alanine aminotrans-
ferase (ALT) concentration (as a proxy for
fatty liver). As shown in Fig. 3, a higher
ApoC3 enrichment of triglycerides was
associated with lower body fat percent
and lower serum ALT both in men and
women.
CONCLUSIONSdThe main ﬁndings
of the current study are as follows: 1) the
association of HDL cholesterol with insu-
lin sensitivity is partially mediated by
BMI, largely attributable to the tight corre-
lation with plasma adiponectin, and unre-
lated to ApoA1 and 2) the association
between triglycerides and insulin sensitivity
is mediated by BMI and FFA and is un-
related to either ApoE or ApoB, whereas it
is inﬂuenced by ApoC3, which appears to
protect tissues from the negative impact
of excess plasma lipid availability.
The lack of association between
ApoA1 and insulin sensitivity in our
study is in contrast with experimental
studies in ob/ob mice, in which treatment
with an ApoA1 mimetic (L-4F) was able
to reduce fat depots, inﬂammation, and
insulin resistance (2). The ob/ob mouse
model is characterized by a high level of
inﬂammation sustained by lipid peroxi-
dation, which, in turn, can be effectively
prevented by L-4F supplementation (2).
Figure 2dA: Regression lines and 95% CI for the slopes of insulin sensitivity (M/I) vs. ApoC3
(top) in univariate (gray) and after adjusting (black) for triglycerides. B: Regression lines and
95%CI for the slopes of insulin sensitivity (M/I) vs. triglycerides in univariate analysis (gray) and
after adjusting for ApoC3 (black). In the inset, the values of the slopes are presented separately for
men and women in both univariate and bivariate regression. P values indicate the level of sta-
tistical signiﬁcance of the comparison between the slopes. Tg, triglyceride.
Figure 3dBody fat % (A) and serum ALT (B)
in female (light gray histogram) and male
(dark gray histogram) according to tertiles of
the ratio ApoC3/triglycerides. P values indicate
the statistical signiﬁcance of the ANOVA. Tg,
triglyceride.
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In our population, the presence of low-
grade inﬂammation, as estimated from
high-sensitivity C-reactive protein .3
units/L, was present in only 7% of the
participants and was unrelated to obesity,
lipids, or insulin sensitivity (A. Natali,
personal communication). In addition,
the treatment of ob/ob mice with the
ApoA1 mimetic was associated with an
increase in plasma adiponectin, an effect
that has been attributed to the decreased
oxidative stress (25). We cannot exclude
that in some speciﬁc, more extreme con-
ditions (such asmorbid obesity), pharma-
cological manipulations of ApoA1 might
result in measurable effects on body fat
and/or insulin sensitivity. Our observa-
tion that ApoA1 variability, at least within
the physiologic range, in humans is un-
likely to affect insulin sensitivity is consis-
tent with a recent elegant experiment in
type 2 diabetic patients, in whom a 4-h in-
fusion of reconstituted HDL particles dou-
bled serum ApoA1 concentrations and
increased HDL cholesterol by 20% but
had no effect on insulin sensitivity (26).
According to our analysis, the associ-
ation between HDL cholesterol and in-
sulin sensitivity is largely attributable to
the fact that low HDL cholesterol is
consistently accompanied by high trigly-
cerides, obesity, low physical activity, and
low plasma adiponectin. In this regard, it
is interesting to note that the strength of
the association between adiponectin and
HDL cholesterol was much stronger than
the ones observed with traditional HDL
correlates such as triglycerides, sex, cen-
tral fat distribution, alcohol, physical
activity, age, and smoking. The fact that
adiponectin has been shown in vivo in
humans to reduce ApoA1 fractional cat-
abolic clearance (27), and that HDL is able
to induce adiponectin expression in vis-
ceral adipocytes in mice (4), is likely to
justify the strong association between
this lipoprotein and the adipokine.
Although experiments in genetically
modiﬁed animals have shown that ApoE
modulates diet-induced fat accumulation
and insulin resistance (15), our data indi-
cate that in humans, and within its phys-
iological range of variability, ApoE does
not seem to play a major role in either fat
deposition or insulin action. In univariate
analysis, ApoE was positively associated
with indices of body fat (waist girth: r =
0.19, BMI: r = 0.19, % fat mass: r = 0.16)
and negatively with M/I (r = 20.13), but
also, very strongly, with serum triglycer-
ides (r = 0.41). When serum triglycerides
were included in multivariate models,
ApoE systematically lost statistical signif-
icance whereas triglycerides remained
signiﬁcantly associated with both obesity
and insulin sensitivity. All the univariate
associations of ApoE were stronger in
men than in women, but the overall pat-
tern of relationships in multivariate anal-
ysis was not different in the two sexes, nor
did the use of the ApoC3/ApoE ratio add
any additional power to our analysis.
With regard to ApoC3, our ﬁndings
are consistent with the observations in
genetically manipulated animals where
this apolipoprotein appears to modulate
insulin sensitivity by reducing the nega-
tive impact of triglycerides on insulin
action and by limiting extravascular fat
deposition (9). The epidemiological stud-
ies that have observed positive associa-
tions between ApoC3 and components
of the metabolic syndrome (10,12) have
failed to take into account the fact that the
role of ApoC3 cannot be inferred without
simultaneously adjusting for serum tri-
glycerides. What appears to be of physio-
logical importance is the lipoprotein
relative enrichment in ApoC3, since the
antilipolytic effect of this apolipoprotein
is mainly physical, i.e., acting as a shield
in the interaction between VLDL and en-
dothelial lipoprotein lipase. By limiting
triglyceride hydrolysis, ApoC3 reduces
FFA availability. In our population, fast-
ing ApoC3 levels had no direct inﬂuence
on circulating FFA concentrations; the
major determinants were body fatness,
sex, and triglycerides. However, ApoC3
tertiles were associated with progressively
lower values of the ratio FFA to triglycer-
ides both in women (98 6 45, 82 6 45,
and 66 6 32 mEq/mg) and men (69 6
39, 52 6 29, and 41 6 26 mEq/mg,
both P , 0.0001). The phenomenon is
expected to be even more important in
the postabsorptive state, where plasma
FFAs are mainly derived from lypolysis
of circulating lipoprotein. On a chronic
basis, a restrained lipoprotein lipolysis
would reduce lipid transfer from the vas-
cular to the extravascular space; this may
translate into reduced tissue exposure to
lipotoxicity. It is therefore not surprising
that ApoC3was an independent predictor
of insulin sensitivity both alone (possibly
by limiting fat depots) and in a negative
interaction with serum triglycerides (pro-
tecting peripheral tissues from VLDL-
derived FFAs). Despite these favorable
metabolic interactions, ApoC3 might
well be a cardiovascular risk factor (11)
because it exerts a direct negative action
on the vascular endothelium (28) and
because it lowers VLDL and IDL clear-
ance, thereby prolonging their exposure
to the vascular wall (6).
As our study is based on cross-sectional
data, our conclusions on the nature of
the observed associations are largely
speculative. In order to limit the inherent
risk in this approach, we carried out our
analyses according to predeﬁned hypoth-
eses that were based on known physiol-
ogy and experimental data. Therefore, we
only make plausible inferences on the
mechanisms underlying the regulation of
tissue insulin sensitivity; clearly, ad hoc–
designed clinical studies are needed to
conﬁrm our ﬁndings. In addition, the
characteristics of our population (essen-
tially healthy subjects) conﬁne the validity
of our conclusion to the physiological
domain; it is possible that in some path-
ological conditions (e.g., severe hypertri-
glyceridemia, hyperglycemia, or morbid
obesity), lipid regulation of insulin sensi-
tivity might be different.
In conclusion, we cannot conﬁrm that
HDL lipoproteins directly exert a relevant
role in modulating insulin sensitivity, the
association between the two being ex-
plained mostly by confounders and in
part by adiponectin. Conversely, we con-
ﬁrm that triglycerides exert a direct nega-
tive inﬂuence on insulin sensitivity and we
provide strong support to the possibility
that ApoC3, by controlling the lipid trans-
fer from plasma to tissues, protects from
the negative action of these substrates.
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